Leander Van Neste

发表

Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination

Patrick Pauwels, Luc Y. Dirix, Peter B. Vermeulen, 2010, PloS one.

Analysis of DNA methylation in cancer: location revisited

Tim De Meyer, Wim Van Criekinge, Zheng Feng, 2018, Nature Reviews Clinical Oncology.

CHFR Promoter Methylation Indicates Poor Prognosis in Stage II Microsatellite Stable Colorectal Cancer

Matty P Weijenberg, J. Herman, L. van Neste, 2013, Clinical Cancer Research.

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

Nita Ahuja, Yi Cai, Yoon-Young Jang, 2012, Cancer cell.

Spectrin Repeat Containing Nuclear Envelope 1 and Forkhead Box Protein E1 Are Promising Markers for the Detection of Colorectal Cancer in Blood

Nita Ahuja, J. Herman, K. Schuebel, 2014, Cancer Prevention Research.

Epigenetic risk score improves prostate cancer risk assessment

Wim Van Criekinge, William E. Grizzle, L. van Neste, 2017, The Prostate.

Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation.

Matteo Pellegrini, Guoping Fan, Alexander Meissner, 2008, Cell stem cell.

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

Geert Trooskens, Wim Van Criekinge, Theo M de Reijke, 2016, European urology.

Convergence of Mutation and Epigenetic Alterations Identifies Common Genes in Cancer That Predict for Poor Prognosis

Leslie Cope, Nita Ahuja, L. Cope, 2008, PLoS medicine.

Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.

Wim Van Criekinge, David J Harrison, L. V. Neste, 2013, The Journal of urology.

Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells.

Wim Van Criekinge, Leslie Cope, Kelly M. McGarvey, 2008, Cancer research.